Kosan Buy Puts BMS Front And Center In HSP90 Race, Strengthens Epothilone Position
This article was originally published in The Pink Sheet Daily
Executive Summary
BMS gains several clinical-stage oncology programs with agreement to acquire Kosan for $190 million.
You may also be interested in...
AstraZeneca/Infinity’s Hsp90 Inhibitor Fails Phase II Prostate Cancer Study
Phase III study of IPI-504 in gastrointestinal cancer still on track for later this year.
AstraZeneca/Infinity’s Hsp90 Inhibitor Fails Phase II Prostate Cancer Study
Phase III study of IPI-504 in gastrointestinal cancer still on track for later this year.
AstraZeneca/Infinity’s Hsp90 Inhibitor Advances In GIST
Positive PFS data in patients treated with retaspimycin presented at ASCO; Phase III to start in third quarter.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: